Pathology Home Diagnostic Tests Consultations faculty index Fellowships index Research index Residency index
Christopher Corless, MD, PhD
Vice Chair, Research
Chief Medical Officer, Knight Diagnostic Laboratories
Rank: Professor
Clinical Services: Surgical Pathology
Clinical Interests: Liver Transplant Pathology, Gastrointestinal Pathology, Genitourinary Pathology
Research Interests: Role of oncogenic mutations in GI stromal tumors, melanomas, and other solid tumors. Development and application of new molecular diagnostic assays for use in research and clinical trials. Further information can be found on the Corless research page.
 
Education:
1981    University of California, Berkeley - BA
1988    Washington University, St. Louis - MD, PhD

Training:

1988-93  Department of Pathology, Brigham and Womens Hospital, Boston

    Residency in Anatomic Pathology
    Fellowship in Gastrointestinal Pathology
    Fellowship in Gentourinary Pathology
Boards:
Anatomic Pathology
Previous Position:
1993-94   Department of Pathology, Brigham and Womens Hospital
                Instructor in Pathology, Harvard Medical School
Selected References:
  • Troxell ML, Levine J, Beadling C, Warrick A, Dunlap J, Presnell A, Patterson J, Shukla A, Olson NR, Heinrich MC, Corless CL. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol. 23(1):27-37, 2010.
  • Long KB, Butrynski JE, Blank SD, Ebrahim KS, Dressel DM, Heinrich MC, Corless CL, Hornick JL. Primary Extragastrointestinal Stromal Tumor of the pleura: Report of a unique case with genetic confirmation. Am J Surg Pathol. 34(6):907-912, 2010.
  • Demetri GD, Heinrich MC, Fletcher JA, Fletcher CDM, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with the multitargeted tyrosine kinase inhibitor sunitinib malate after imatinib failure. Clin. Cancer Res 15(18):5902-9, 2009.
  • Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CDM. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: A novel form of tumor progression. Am J Surg Pathol 33(2):218-26, 2009.
  • Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. KIT Gene Mutations and Copy Number in Melanoma Subtypes. Clin Cancer Res. 14(21):6821-8, 2008.
  • Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 26(33):5352-9, 2008.
  • Liegl B, Kepten I, Le C, Demetri GD, Heinrich MC, Fletcher CDM, Corless CL, Fletcher JA. Substantial heterogeneity of kinase inhibitor resistance mechanisms in GIST. j Pathology 216(1):64-74, 2008.
  • Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE A Major Response to Imatinib Mesylate in KIT Mutated Melanoma. J Clin Onc 26:2046-51, 2008.

Last Updated: 02/17/2010